• 1.第四軍醫(yī)大學(xué)西京醫(yī)院普二科（西安710032）;;
  • 　2.第四軍醫(yī)大學(xué)西京醫(yī)院普一科;;
  • 　3.第四軍醫(yī)大學(xué)病理學(xué)教研室;

目的 探討p27KIP1與原發(fā)性肝細(xì)胞癌（HCC）發(fā)生、發(fā)展的關(guān)系。方法應(yīng)用SABC（鏈霉素親和素生物素復(fù)合物）免疫組化染色和mRNA原位雜交方法，對52例肝細(xì)胞肝癌中p27KIP1蛋白和mRNA的表達(dá)進(jìn)行了檢測。結(jié)果 p27KIP1基因的表達(dá)主要位于肝或肝癌細(xì)胞的細(xì)胞核中，呈細(xì)顆粒狀分布。 p27KIP1蛋白在癌旁肝組織中的陽性細(xì)胞指數(shù)為（10.7±7.6）%，明顯高于癌組織的（1.5±0.9）%，并且p27KIP1蛋白表達(dá)的陽性細(xì)胞指數(shù)與HCC細(xì)胞的分化程度呈正相關(guān)。p27KIP1　mRNA雜交陽性物呈藍(lán)色細(xì)顆粒狀，主要位于肝或肝癌細(xì)胞的細(xì)胞核和細(xì)胞漿中，mRNA陽性的細(xì)胞分布更廣泛，但在癌旁肝組織和不同分化程度的HCC組織中，p27KIP1mRNA的陽性細(xì)胞指數(shù)差異無顯著性意義。結(jié)論p27KIP1蛋白與HCC的發(fā)生及細(xì)胞分級有關(guān)。

引用本文： 鄭建勇,李開宗,王為忠,李江. 肝細(xì)胞肝癌中p27KIP1基因的表達(dá)及意義. 中國普外基礎(chǔ)與臨床雜志, 2003, 10(3): 240-242. doi: 復(fù)制

1. Lloyd RV, Erickson LA, Jin L, et al. p27KIP1, a multifunctional cyclindependent kinase inhibitor with prognostic significance in human cancers [J]. Am J Pathol, 1999; 154(2)∶ 313.
2. Peng D, Fan Z, Lu Y, et al. Antiepidexmal growth factor receptor monoclonal antibody 225 upregulates p27KIP1and induces G1 arrest in prostatic cancer cell line DU1451 [J]. Cancer Res, 1996; 56（16）∶ 3666.
3. Polyak K, Kato JY, Solomon MJ, et al. p27KIP1, a cyclinCDK inhibitor; links transforming growth factorbeta and contact inhibition to cell cycle arrest [J]. Genes Dey, 1994; 8（1）∶ 9.
4. 郭貴龍，姚榛祥. p27在甲狀腺濾泡狀腫瘤中的表達(dá)及其意義 [J]. 中國普外基礎(chǔ)與臨床雜志， 2001； 8（5）∶ 324.
5. 夏加增，楊繼昌，張熔熔,等. 胃癌中cyclin D1、cyclin E和p27的表達(dá)及其意義 [J]. 中國普外基礎(chǔ)與臨床雜志， 2001； 8（3）∶ 148.
6. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclindependent kinase inhibitor p27KIP1 is a novel prognostic factor in localized human prostate adenocarcinoma [J]. Cancer Res, 1998; 58（3）∶ 542.
7. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in human malignancies [J]. Cancer Res, 1995; 55（11）∶ 2266.
8. Zhang Y, Lin SC. Molecular characterization of the cyclindependent kinase inhibitor p27 promoter [J]. Biochim Biophys Acta, 1997; 1353(3)∶ 307.
9. Loda M, Cukor B, Tam SW, et al. Increased proteasomedependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas [J]. Nat Med, 1997; 3（2）∶ 231.
  1. 1. Lloyd RV, Erickson LA, Jin L, et al. p27KIP1, a multifunctional cyclindependent kinase inhibitor with prognostic significance in human cancers [J]. Am J Pathol, 1999; 154(2)∶ 313.
  2. 2. Peng D, Fan Z, Lu Y, et al. Antiepidexmal growth factor receptor monoclonal antibody 225 upregulates p27KIP1and induces G1 arrest in prostatic cancer cell line DU1451 [J]. Cancer Res, 1996; 56（16）∶ 3666.
  3. 3. Polyak K, Kato JY, Solomon MJ, et al. p27KIP1, a cyclinCDK inhibitor; links transforming growth factorbeta and contact inhibition to cell cycle arrest [J]. Genes Dey, 1994; 8（1）∶ 9.
  4. 4. 郭貴龍，姚榛祥. p27在甲狀腺濾泡狀腫瘤中的表達(dá)及其意義 [J]. 中國普外基礎(chǔ)與臨床雜志， 2001； 8（5）∶ 324.
  5. 5. 夏加增，楊繼昌，張熔熔,等. 胃癌中cyclin D1、cyclin E和p27的表達(dá)及其意義 [J]. 中國普外基礎(chǔ)與臨床雜志， 2001； 8（3）∶ 148.
  6. 6. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclindependent kinase inhibitor p27KIP1 is a novel prognostic factor in localized human prostate adenocarcinoma [J]. Cancer Res, 1998; 58（3）∶ 542.
  7. 7. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in human malignancies [J]. Cancer Res, 1995; 55（11）∶ 2266.
  8. 8. Zhang Y, Lin SC. Molecular characterization of the cyclindependent kinase inhibitor p27 promoter [J]. Biochim Biophys Acta, 1997; 1353(3)∶ 307.
  9. 9. Loda M, Cukor B, Tam SW, et al. Increased proteasomedependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas [J]. Nat Med, 1997; 3（2）∶ 231.